and was attended by 168 delegates from 28 countries. The conference provided a forum for professionals involved in basic science, clinical research, regulatory affairs, and clinical care to meet and discuss the latest advances related to discovery and development of drugs and devices aimed at improving the management of people with epilepsy. This progress report provides a summary of findings on investigational compounds for which data from both preclinical studies and studies in patients were presented. The compounds reviewed include anakinra, cannabidiol, cannabidivarin, fenfluramine, ganaxolone, medium-chain fatty acids, padsevonil, and the valproic derivatives valnoctamide and sec-butylpropylacetamide. On June 25, 2018, the US Food and Drug Administration approved a standardized formulation of cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients 2 years and older. The report shows that there continues to be a steady flow of potential antiepileptic drugs progressing to clinical development. Many of these compounds show innovative mechanisms of action, and some have already been tested in placebo-controlled randomized controlled trials, with promising efficacy and safety results.
| INTRODUCTION
The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV) took place in Madrid, Spain, on May 13-16, 2018 and was attended by 168 delegates from 28 countries. As explained in some detail in an accompanying report, 1 the conference allowed professionals actively engaged in basic science, clinical research, regulatory affairs, and clinical care to meet and discuss key topics related to antiepileptic drug (AED) discovery and development. Additionally, the conference offered the opportunity to review data on a number of novel agents that are currently being investigated as potential epilepsy treatments. Devices used for the detection or treatment of seizures were also discussed, and a summary of the presentations on this topic will be reported in a separate publication. The accompanying report summarizes the latest findings for 12 different compounds (or classes of compounds) for which preclinical or early phase (phase I) clinical data were presented. 1 The current report focuses on eight compounds/ classes of compounds in more advanced clinical development, for which at least preliminary results from efficacy and safety studies conducted in patients were made available. Specifically, these agents include anakinra, cannabidiol, cannabidivarin, fenfluramine, ganaxolone, medium-chain fatty acids, padsevonil, and the valproic derivatives valnoctamide and sec-butylpropylacetamide. For each of these compounds, a concise description of preclinical data, clinical pharmacokinetic data, drug interaction potential, and available efficacy and safety results is provided in the sections below.
| ANAKINRA
Elaine Wirrell Child and Adolescent Neurology, Mayo Clinic, Rochester, Minnesota
| Introduction and rationale for development
Anakinra, a protein consisting of 153 amino acids with a molecular weight of approximately 17.3 kDa, is a recombinant human interleukin (IL)-1 receptor antagonist that is approved for the treatment of rheumatoid arthritis and cryopyrin-associated periodic syndromes such as neonatal onset multisystem inflammatory disease, Muckle-Wells syndrome, and familial cold autoinflammatory syndrome. 2 Due to its ability to block IL-1β, anakinra may represent a novel therapy to attenuate maladaptive neurogenic inflammation and epileptogenesis.
There is abundant evidence for an inflammatory contribution to human epilepsy. Pathological evidence of neurogenic inflammation has been found in human epilepsy surgery specimens with cortical dysplasia and tuberous sclerosis complex, 3 gangliogliomas and dysembryoplastic neuroepithelial tumors, 3 and Rasmussen syndrome. 4 Furthermore, higher seizure frequency correlated with higher numbers of IL-1β and IL-1 receptor type 1-positive neurons. Greater susceptibility to neurogenic inflammation may also play a role in predisposition to febrile seizures, a disorder that affects 3%-5% of all children. In a study evaluating polymorphisms in two regions of the IL-1β promotor region in children with and without febrile seizures, Ozen et al 5 noted significant differences in one of these regions, suggesting that those with febrile seizures may be
Key Points
• The Eilat Conference on New Antiepileptic Drugs and Devices is a biannual event focused on discussing advances in the development of new treatments for epilepsy • The Fourteenth Conference took place in Madrid, Spain, on May 13-16, 2018 and was attended by 168 scientists from 28 countries • This article summarizes findings presented at the conference for eight compounds (or classes of compounds) for which data from studies in patients are already available • Some of these compounds have new mechanisms of action, such as targeting neuroinflammation, interacting with novel receptor types, or combining dual receptor action into a single molecular entity • Many of the compounds presented have innovative mechanisms of action and, for some, promising evidence of efficacy has already been provided through randomized controlled trials more susceptible to neurogenic inflammation. In the large FEBSTAT (Consequences of Prolonged Febrile Seizures in Childhood) study, plasma cytokines were compared between children with prolonged febrile seizures and those with fever only. 6 Both IL-8 and epidermal growth factor were significantly higher in the seizure cohort. Furthermore, the native human IL-1 receptor antagonist (IL-1RA)/ IL-6 ratio was significantly lower in children with prolonged febrile seizures and abnormal T2 hyperintensity in the mesial temporal region on magnetic resonance imaging than in those with seizures but normal magnetic resonance imaging, suggesting that this ratio may be a marker for acute hippocampal injury. There is also substantial evidence for a role of neurogenic inflammation in the pathogenesis of febrile infectionrelated epilepsy syndrome (FIRES), a devastating disorder in which a previously well child presents with refractory status epilepticus (SE) following a febrile illness. 7 Mortality is high, and survivors are typically left with intractable, multifocal epilepsy and intellectual disability. No infectious, autoimmune, or metabolic etiologies have been found despite extensive evaluation, and it is presumed that this disorder results from a fulminant inflammatory response in the brain. Sakuma et al 8 compared levels of both plasma and cerebrospinal fluid (CSF) cytokines in 27 cases of FIRES, 14 children with other inflammatory neurological disorders, and 18 children with noninflammatory neurological disorders and found markedly increased proinflammatory cytokines and chemokines in the FIRES cohort, particularly in the CSF. A candidate gene analysis comparing polymorphisms of cytokine-related and sodium channel genes in 19 children with FIRES to healthy controls found a significant association in the RN2 allele of ILIRN and FIRES. 9 This allele results in higher levels of IL-1β
and lower levels of IL-1RA, suggesting that those with FIRES may have an underlying genetic predisposition to excessive neurogenic inflammation. Together with evidence in experimental models, these data provide a rationale for testing anakinra as a potential antiseizure/antiepileptogenic agent, particularly in syndromes where neurogenic inflammation appears to play an important pathogenetic role, such as FIRES.
| Pharmacology

| Anticonvulsant profile
Anakinra, when administered after bicuculline in the in vitro isolated guinea pig brain, rapidly terminated seizures, prevented their recurrence, and resolved seizure-associated breakdown of the blood-brain barrier. 10 In addition, anakinra ameliorated memory impairment associated with pentylentetrazole (PTZ)-induced seizures. 11 Anakinra does not directly modulate neuronal excitability but reduces only the periodic bursting of seizures and may reduce the synchronization associated with the bursting phase. 10 
| Mechanism of action
Work in rodent models documented a proconvulsant role for IL-1β. In epileptogenesis, both astrocytes and endothelial cells of the blood-brain barrier release IL-1β, which results in ongoing neuronal injury and blood-brain barrier leakage. 10, 12 Conversely, IL-1RA has been shown to have an anticonvulsant role. 13 Work in immature animals has shown that IL-1RA blocks kindling and mitigates augmentation of epileptogenesis enhanced by lipopolysaccharide.
14 Neurogenic inflammation is evoked by neuronal activity and contributes to epileptogenesis. The IL-1/Toll-like receptor 4 system is key to neurogenic inflammation, and the main ligands are IL-1β and high-mobility group box 1 (HMGB1). Under normal conditions, HMGB1 is located in the nucleus and regulates gene transcription. After inflammasome activation, HMGB1 translocates to the cytoplasm and activates Toll-like receptor 4, thus exacerbating neurogenic inflammation. 15 These inflammatory mediators directly affect neuronal excitability by rapid posttranscriptional effects on receptors and ion channels, and induce Src kinase-dependent phosphorylation of the NR2B subunit of the N-methyl-D-aspartate receptor, which increases calcium influx.
Anakinra is a recombinant human IL-1 receptor antagonist that, unlike the native protein (IL-1RA), is not glycosylated and has an additional N-terminal methionine. The compound blocks the effects of IL-1 by competitively inhibiting the binding of IL-1α and IL-1β to the IL-1 receptor. 16 
| Pharmacokinetics
Anakinra is administered by subcutaneous injection and has a half-life of approximately 4-6 hours in adults.
2 Following subcutaneous injection, its bioavailability is approximately 95%. Anakinra is eliminated renally, and thus dosing must be adjusted for renal impairment. 2 In cryopyrin-associated periodic syndromes, the typical starting dose of anakinra is 1-2 mg/kg/d, and the dose may be increased according to clinical response to a maximum of 8 mg/kg/d. One study evaluated the population pharmacokinetics of anakinra in 87 children and adolescents aged 8 months to 21 years and found that a one-compartment model with linear absorption and elimination described the pharmacokinetics in these patients. 17 The apparent oral clearance (CL/F) estimated according to the model was 6.24 L/h/70 kg.
| Drug interactions
There is evidence that increased levels of cytokines (eg, IL-1) during chronic inflammation may result in reduced cytochrome P450 (CYP) enzyme activity. Theoretically, use of IL-1RAs, such as anakinra, in patients with chronic inflammation could normalize CYP activity and modify the serum concentrations of drugs metabolized by these enzymes 2 ; however, this has yet to be demonstrated.
| Efficacy data
A single case report on the use of anakinra in FIRES has been published, 18 and an additional two cases have been presented in abstract form. 19, 20 In the published case, a 32-month-old girl was commenced on anakinra 6 mg/kg twice daily (b.i.d.) on day 6 with marked reduction in seizures. Anakinra was then stopped on day 23, but was restarted again on day 54, due to recurrent SE, with marked improvement. Cytokine analysis showed marked elevations in IL-6 and IL-8 in her CSF but not her serum, suggesting that inflammatory cytokines were being produced in the CSF. After long-term follow-up, she had only occasional seizures, and her motor, verbal, and social development was within normal limits for age based on clinical examination alone, although imaging studies showed diffuse brain atrophy. Both cases presented in abstract form started anakinra on day 13 (personal communication from Dr. K. Eschbach), and although this was associated with a marked seizure reduction, long-term outcome was still poor. A small, retrospective case series of four children with intractable epilepsy and comorbid specific polysaccharide antibody deficiency showed seizure reduction with anakinra therapy (marked in 2/4 cases) with exacerbation noted with dose reduction or discontinuation. 21 
| Tolerability and side effect profile
The most common adverse effect of anakinra is injection site reaction, and this is usually seen in the first 4 weeks of treatment. 2 Other common side effects include headache, nausea, vomiting, and pyrexia. Hypersensitivity reactions ranging from rash to anaphylaxis may occur. Anakinra rarely results in neutropenia and/or thrombocytopenia and may increase the risk of infection. Risk of malignancy, particularly lymphoma, is uncommon (0.12/ 100 patient-years). Finally, anakinra may induce immunogenicity, with up to 3% of patients testing positive for neutralizing antibodies after 12 weeks of treatment.
| Planned studies
A multicenter study of early use of anakinra in children with FIRES is in the planning stages. 
| CANNABIDIOL
| Introduction and rationale for development
Cannabidiol is a first-in-class AED. It is the second most abundant phytocannabinoid derived from the Cannabis sativa plant, which has been found to possess protective effects in preclinical models of epileptiform activity, seizures, and epilepsy. 22 More recently, antiseizure effects of cannabidiol have been demonstrated in clinical trials of childhood onset epilepsies. Although the precise mechanisms by which cannabidiol exerts its antiseizure effect in humans remain unknown, cannabidiol lacks appreciable interaction with cannabinoid receptors, 23 which likely also accounts for its apparent lack of euphoric effects. With 20 years of experience in cannabinoid science, GW Pharmaceuticals has initiated a preclinical and clinical development program investigating the potential therapeutic application of cannabinoids across a wide range of disease states. GW is currently involved in six phase II/III studies designed to evaluate the safety and efficacy of a plantderived liquid pharmaceutical formulation of highly purified cannabidiol (Epidiolex), as add-on treatment, across four drug-resistant epilepsy conditions: Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. On June 25, 2018, Epidiolex was approved by the US Food and Drug Administration (FDA) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years and older, pending US Drug Enforcement Administration rescheduling from Schedule I, which refers to drugs with no currently accepted medical use and a high potential for abuse. It is currently under review by European regulatory authorities for the treatment of drug-resistant seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
| Pharmacology
| Activity profile in experimental seizure and epilepsy models
Cannabidiol demonstrated efficacy in hippocampal slice models of epileptiform activity indicative of SE, significantly reduced the number of seizures in a model of temporal lobe seizures, and significantly reduced the incidence of seizure-related mortality in an intracerebroventricular penicillin model of focal seizures, and when coadministered with ethosuximide or valproic acid in an acute PTZ seizure model. It retained its anticonvulsant effect, was well tolerated, and demonstrated additive or synergistic interactions with valproic acid in the latter model. 22 The mouse maximal electroshock seizure threshold test, a model of generalized seizures, was used to confirm central nervous system (CNS) penetrance and assesses antiseizure activity of two human metabolites of cannabidiol, that is, 7-hydroxy-cannabidiol and 7-carboxy-cannabidiol. Cannabidiol and 7-hydroxy-cannabidiol, but not 7-carboxycannabidiol, significantly reduced the incidence of hindlimb extension in this model when compared with vehicle. 24 Furthermore, the anticonvulsant and tolerability profile of cannabidiol was independently examined in the Epilepsy Therapy Screening Program, where effects were verified and further characterized in a battery of well-established rodent seizure models. 25, 26 In a pharmacoresistant mouse model of Dravet syndrome, cannabidiol significantly prolonged the median survival of SCN1α heterozygotes and null animals and had no effect on the welfare of wild-type mice. Cannabidiol significantly improved weight gain and delayed the worsening of the neonatal welfare score, natural activity, response to touch, orbital tightening, and body condition score of SCN1α null animals. 27 In a lithium-pilocarpine-induced rat model of temporal lobe epilepsy, repeated cannabidiol treatment improved seizures and epilepsy-associated comorbidities in rats. Cannabidiol reduced spontaneous seizures, reversed epilepsy-induced motor dysfunction, did not have any adverse effect on gait of temporal lobe epilepsy animals, and ameliorated epilepsy-induced memory deficits (GW Pharmaceuticals, data on file). 
| Other pharmacological properties
| Toxicology
In a 2-year carcinogenicity study in rats (HsdBrlHan: WIST), oral dietary administration of cannabidiol (5, 15, 50 mg/kg/d) in the form of a botanical drug substance extract resulted in no effect on tumor formation, no increase in the incidence of neoplasia, no alteration in the time of tumor onset, and no induction of rare tumors. There was, however, a reduced incidence of tumors (pituitary and mammary) generally associated with hormonally mediated neoplasia in aging animals. Cannabidiol was not mutagenic in the in vitro Ames test and was not clastogenic in the in vitro mammalian cell chromosomal aberration assay or in the in vivo rat Comet and bone marrow micronucleus assays (GW Pharmaceuticals, data on file).
| Pharmacokinetic and metabolic profile
After oral administration of ascending single doses of cannabidiol (1500-6000 mg) to healthy volunteers, peak plasma concentration (C max ) and area under the plasma concentration versus time curve (AUC) increased, with a trend to less than dose proportionality. Disproportionality was not seen after multiple dosing. For a twofold increase in dose over 7 days (750 or 1500 mg/d), there was nearly a doubling in exposure (GW Pharmaceuticals, data on file). Cannabidiol oral bioavailability has been estimated to be 6%. 30 When given orally as GW Pharmaceuticals' formulation, cannabidiol appears rapidly in plasma, with a time to maximum plasma concentration (t max ) of 2. CYP2C19 is the major CYP isoform involved in the metabolism of cannabidiol to 7-hydroxy-cannabidiol, an active metabolite that is metabolized further by CYP3A4 to 7-carboxy-cannabidiol. After multiple dosing with cannabidiol, the 7-hydroxy-cannabidiol metabolite circulates in human plasma at the same order of magnitude as cannabidiol based on AUC. The UDP-glucuronosyltransferase (UGT) isoforms responsible for the phase II conjugation of cannabidiol are UGT1A7, UGT1A9, and UGT2B7. Cannabidiol is predominantly cleared by metabolism in the liver and gut and excreted in feces, and to a much lesser extent in the urine. 
| Drug interactions
A phase I repeated dose study in healthy volunteers showed a bidirectional interaction between clobazam and cannabidiol leading to increases in exposure to the active metabolites of both compounds. 31 In that study, there was no important increase of clobazam parent compound exposure when cannabidiol (750 mg b.i.d., 7-14 days) was added to clobazam (5 mg b.i.d., 7-14 days). There was, however, a notable elevation of the active metabolite Ndesmethylclobazam of 3.4-fold for both C max and AUC, likely mediated by CYP2C19 inhibition. When clobazam was added to cannabidiol, there was an increase in exposure to the active metabolite 7-hydroxy-cannabidiol (C max = 1.7-fold, AUC 0-t = 1.5-fold), possibly mediated by inhibition of UGTs. 31 In 13 children (age = 4-19 years) with refractory epilepsy taking cannabidiol and clobazam, clobazam levels increased at 4 weeks by a mean of 60 ± 80% and N-desmethylclobazam levels increased by a mean of 500 ± 300%. 
| Efficacy data
Three randomized, double-blind, placebo-controlled, multicenter trials have been completed for add-on cannabidiol in the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Patients were encouraged to take their medication in a consistent manner with respect to food, and there were no specific recommendations for taking cannabidiol with or without food. The trials demonstrated that GW Pharmaceuticals' formulation of purified cannabidiol (≥98% cannabidiol, with trace residual amounts of delta-9-tetrahydrocannabinol with a maximum of 0.1% wt/wt in active pharmaceutical ingredient, and other plant components) was significantly superior to placebo in reducing seizure frequency over a 14-week treatment period (2-week titration plus 12-week maintenance) in patients with these syndromes. Nearly all (98%) patients who completed the trials entered an ongoing open-label extension study. In GWPCARE1 (NCT02091375), 120 children and adults with Dravet syndrome (mean age = 9.8 years, 52% male) and drug-resistant seizures received either cannabidiol oral solution at a dose of 20 mg/kg/d or placebo given in two equally divided doses, in addition to standard antiepileptic treatment. Patients had a median of 13. The median monthly frequency of total seizures of all types was significantly reduced with cannabidiol (P = 0.03). There was no significant reduction (P = 0.88) in nonconvulsive seizures (myoclonic, countable focal, other focal, absence). 33 In GWPCARE4 (NCT02224690), 171 children and adults with Lennox-Gastaut syndrome (mean age = 15.4 years, 51.5% male) received either oral cannabidiol solution at a dose of 20 mg/kg/d or placebo given in two equally divided doses, in addition to standard antiepileptic treatment. Patients had previously discontinued a median of six AEDs, were taking a median of three concomitant AEDs, and had a median of 73.8 drop seizures during the 4-week baseline period. The monthly frequency of drop seizures decreased by a median of 44% (IQR = −69.6 to −1.9) for cannabidiol compared with a median of 22% (IQR = −45.7 to 1.7) for placebo, with an estimated median difference of −17.2 (95% CI = −30.3 to −4.1, P = 0.0135) between the groups. 34 In GWPCARE3 (NCT02224560), 225 children and adults with Lennox-Gastaut syndrome (mean age = 16 years, 57.3% male) received either oral cannabidiol solution at a dose of 10 or 20 mg/kg/d or placebo given in two equally divided doses. Patients had a median of 85 drop seizures during the 4-week baseline period. The monthly frequency of drop seizures decreased by a median of 37% for 10 mg/kg/d (P = 0.002 vs placebo), 42% for 20 mg/kg/d (P = 0.0005 vs placebo), and 17% for placebo. The estimated median difference in percentage points was −19.2 (95% CI = −31.2 to −7.7, P = 0.002) for the 10 mg/kg/d group and −21.6 (95% CI = −34.8 to −6.7, P = 0.005) for the 20 mg/kg/d group compared with placebo. 35 The difference between treatments favored cannabidiol over placebo during the first 4 weeks of maintenance dosing and persisted throughout the treatment (GW Pharmaceuticals, data on file). 35 In a pooled analysis of the two trials of add-on cannabidiol treatment in patients with Lennox-Gastaut syndrome, more patients or caregivers in the cannabidiol treatment groups reported improvement in overall condition as measured on the Subject/Caregiver Global Impression of Change scale than in the placebo groups. 36 A recent interim analysis of the ongoing open-label extension trial (GWPCARE5; NCT02224573) of add-on cannabidiol in patients with Dravet syndrome (median time on treatment = 39 weeks; 28% with at least 37 weeks) and Lennox-Gastaut syndrome (median time on treatment = 38 weeks; 57% with at least 37 weeks) showed that longterm treatment with cannabidiol was generally well tolerated, with a safety profile similar to the 14-week phase III trials. Long-term cannabidiol was associated with durable reductions in convulsive and total seizure frequency (in Dravet syndrome) and durable reductions in drop and total seizure frequency (in Lennox-Gastaut syndrome). More than 80% of subjects/caregivers reported improvement in overall condition as measured on the Subject/Caregiver Global Impression of Change scale at 24 and 48 weeks. 37, 38 Results from an exposure-response analysis of cannabidiol for the treatment of Lennox-Gastaut syndrome suggest that the observed reduction in drop seizures and onset of certain adverse events (AEs) are related to both cannabidiol and 7-hydroxy-cannabidiol exposure. The drop seizure responder rate (patients with ≥50% reduction) significantly increased with increasing plasma exposure of cannabidiol and its active metabolite 7-hydroxy-cannabidiol. Positive correlations with plasma exposure (AUC) were also determined for several AEs for both cannabidiol and 7-hydroxycannabidiol. 39 A treatment responder analysis in patients with Lennox-Gastaut syndrome on and off clobazam showed that add-on cannabidiol resulted in greater seizure reductions versus add-on placebo, regardless of concomitant use of clobazam. AEs were reported more frequently in patients receiving cannabidiol than in those receiving placebo, with more somnolence observed in patients on versus off clobazam. 34 
| Tolerability and adverse effect profile
A thorough QT study showed that single therapeutic (750 mg) and supratherapeutic (4500 mg) oral doses of cannabidiol do not affect heart rate, pulse rate, or QRS interval duration, QTc, or other electrocardiographic parameters; in addition, there were no treatment-emergent electrocardiographic morphological changes following treatment. 40 Although AEs were more frequent in patients receiving cannabidiol than those receiving placebo, they were of mild or moderate severity in the majority of patients and treatment was generally well tolerated. AEs leading to withdrawal occurred in 13% of patients with Dravet syndrome treated with 20 mg/kg/d compared with 2% for placebo. 33 In patients with Lennox-Gastaut syndrome, AEs leading to withdrawal occurred in 11% treated with 20 mg/kg/d and 1% treated with 10 mg/kg/d compared with 1% for placebo. 36 Common AEs reported across the cannabidiol development program are somnolence, decreased appetite, diarrhea, pyrexia, fatigue, lethargy, rash, nasopharyngitis, and pneumonia. Dose-related, reversible elevations of liver transaminase enzyme levels without meeting Hy's law criteria were observed with cannabidiol treatment, most commonly in patients receiving valproic acid and predominantly within the first month of treatment.
37,38
Resolution of transaminase elevations of ≥5 times the upper limit of the normal range from the randomized controlled trials and the open-label extension trial occurred with the discontinuation of cannabidiol in 53% of cases. In 47% of cases, transaminase elevations resolved during continued treatment with cannabidiol, with or without dose reduction of cannabidiol or valproic acid.
Administration of a single oral dose of cannabidiol (750 mg) showed no significant or consistent abuse potential in a highly sensitive population of recreational polydrug users. 41 Higher doses of cannabidiol (1500 and 4500 mg), which are above those found to be effective in the Dravet and Lennox-Gastaut trials, had detectable subjective effects; however, these were reported significantly less often when compared with the positive controls, alprazolam (2 mg, Schedule IV) and two doses of dronabinol (10 and 30 mg, Schedule III), and were not considered clinically significant. At the doses tested, use of cannabidiol was not associated with cognitive or psychomotor impairment, was well tolerated, and produced few abuserelated AEs, suggesting a low abuse potential. 
| Planned studies
Ongoing studies with cannabidiol include a phase III doseranging study in Dravet syndrome, a phase III study in tuberous sclerosis complex, and a phase II/III study in infantile spasms. Eligible patients from these studies, and from the completed randomized trials summarized above, are participating in ongoing open-label extension trials. Other indications in epilepsy are being considered for future studies. 
| CANNABIDIVARIN
| Introduction and rationale for development
Cannabidivarin is the propyl analog of cannabidiol and is an active constituent derived from the Cannabis sativa plant. Cannabidivarin has shown antiepileptic properties in in vitro models of epileptiform activity and antiseizure properties in in vivo models of seizures. However, the precise mechanisms underlying these effects remain unknown. As part of its cannabinoid development program, GW Pharmaceuticals and its US subsidiary Greenwich Biosciences are investigating the potential therapeutic applications of cannabidivarin across a range of disease states, including epilepsy.
| Pharmacology
| Anticonvulsant profile
The anticonvulsant profile of cannabidivarin has been reported previously in some detail. 22, 42 Cannabidivarin exerted an inhibitory effect on epileptiform discharges in vitro in the 4-aminopyridine model and in the magnesium-free model, using extracellular, multisite electrophysiological recordings from acute rat hippocampal slices. 42 In vivo, cannabidivarin (≥50 mg/kg ip) significantly reduced tonic convulsions, and both hindlimb and forelimb extensions in the mouse maximal electroshock model. Cannabidivarin also reduced the incidence of tonic convulsions in the mouse audiogenic model, with a median effective dose (ED 50 ) of 64 mg/kg ip, and reduced at a dose of 200 mg/kg ip the incidence of tonic-clonic seizures in the acute PTZ rat model. 42 Furthermore, in the acute PTZ rat model, cannabidivarin increased the latency to seizure onset and the number of animals that exhibited no sign of seizure activity. When coadministered with either ethosuximide or valproate in the same model, cannabidivarin (200 mg/kg ip) retained its anticonvulsant effect and did not functionally antagonize the anticonvulsant actions of either drug. 42 Cannabidivarin (200 mg/kg ip) alone had no effect against acute pilocarpine-induced temporal lobe seizures, but significantly attenuated these seizures when administered with valproate or phenobarbital at this dose. 42 Molecular markers of seizures were assessed using the rat PTZ model of acute generalized seizures. Cannabidivarin at a dose of 400 mg/kg per os significantly decreased median seizure severity, increased the latency to seizure onset, and suppressed seizure-related changes in mRNA expression of Fos, Egr1, Arc, Ccl4, and brain-derived neurotrophic factor. 43 Tests of motor function confirmed that the anticonvulsant effects of cannabidivarin (≤200 mg/kg) in models of acute seizures are due to its anti-ictal properties and not to suppression of motor function. Cannabidivarin (50-200 mg/ kg ip) had no significant effects on the static beam and forelimb grip strength tests, in contrast to a therapeutic dose of valproate (125-350 mg/kg ip), which demonstrated a dose-dependent increase in the number of foot slips and the distance traveled on the static beam. 
| Other pharmacological properties
Cannabidivarin has been reported to inhibit the ability of lysophosphatidylinositol to activate G protein-coupled receptor 55, its cognate receptor. 44 Additionally, cannabidivarin is able to rapidly activate and antagonize the transient receptor potential cation channel subfamily V members 1 and 2, which are both members of the vanilloid receptor family. 45 Further work is needed to assess potential similarities and/or differences in effects of cannabidivarin and cannabidiol.
| Mechanism of action
The mechanism underlying the antiseizure effects of cannabidivarin is unknown and is currently under investigation. Importantly, cannabidivarin lacks appreciable affinity and functional activity at human cannabinoid receptor type 1 and does not bind to human cannabinoid receptor type 2 with significant affinity. 42, 43, 46 
| Toxicology
A large body of preclinical toxicological evidence suggests that cannabidivarin has a wide safety margin between the proposed clinical dose and the dose at which the no observed adverse effect level was observed in the nonclinical studies. Although no target organ toxicity has been identified, an adaptive change in liver was noted comprising hepatocyte hypertrophy with an associated change in liver enzymes (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase; GW Pharmaceuticals, data on file).
| Pharmacokinetics and metabolic profile
Pharmacokinetic studies confirmed that 7-hydroxy-cannabidivarin and 7-carboxy-cannabidivarin are metabolites of cannabidivarin. 22 However, the clinical relevance of the abundance of metabolites has yet to be established. A single oral dose study in healthy subjects showed that cannabidivarin C max and AUC were dose proportional in the 200-to 800-mg dose range. 
| Drug interactions
Cannabidivarin is being investigated in adults with focal epilepsy. The first part of a phase II randomized, doubleblind, placebo-controlled study of adjunctive cannabidivarin for the treatment of inadequately controlled focal seizures has been completed. Part A (NCT02369471) evaluated the safety and pharmacokinetics of cannabidivarin in the presence of concomitant AEDs and indicated that there were no appreciable differences in the pharmacokinetics and safety profile of cannabidivarin when given concomitantly. These results supported continuing with Part B of the study without additional exclusions of concomitant medications. One hundred sixty-two patients have now completed Part B (NCT02365610) of this study.
| Efficacy data
A phase II double-blind, randomized, placebo-controlled, two-part study has been conducted to investigate the pharmacokinetics and safety (Part A) and efficacy (Part B) of cannabidivarin as add-on therapy in patients with inadequately controlled focal seizures. Part B randomized 162 patients to cannabidivarin or placebo (1:1) and included a 4-week baseline period and an 8-week treatment period (2-week titration starting with 400 mg b.i.d., up to 800 mg b.i.d. plus 6-week maintenance) followed by a 12-day taper period. The primary endpoint was the change from baseline in focal seizure frequency in patients taking add-on cannabidivarin compared with add-on placebo. The primary endpoint was not met.
| Tolerability and adverse effect profile
A phase I randomized, double-blind, placebo-controlled trial in healthy subjects showed that cannabidivarin was well tolerated at even the highest tested dose (800 mg once daily over 5 days), and no significant AEs were observed. The overall incidence of AEs was low, with no serious AEs or withdrawals due to AEs. Part A of the phase II trial showed similar results, with no serious AEs or withdrawals due to AEs. In Part B of the phase II trial, serious AEs were reported in 3.7% of patients taking cannabidivarin and 1.2% of patients taking placebo. Withdrawals due to AEs were reported in 13.6% of patients taking cannabidivarin and 2.5% of patients taking placebo (GW Pharmaceuticals, data on file).
| Planned studies
In preclinical models, cannabidivarin is a promising antiseizure agent and has thus far demonstrated a favorable toxicological profile. Its clinical development will include targeting patients with seizure disorders, Rett syndrome, and autism spectrum disorder.
| FENFLURAMINE HYDROCHLORIDE (ZX008)
Gail Farfel
Zogenix Pharmaceutical, Emeryville, California
| Introduction and rationale for development
ZX008 (low-dose fenfluramine HCl) is being developed as an oral solution for the adjunctive treatment of patients with Dravet syndrome. As reported in some detail in the previous Eilat progress report, 22 the rationale for the development of fenfluramine in this indication stems from early observations suggestive of the usefulness of this compound in patients with refractory epilepsy and SCN1A mutations subsequently confirmed to have Dravet syndrome.
| Pharmacology
The activity profile of fenfluramine in a zebrafish model of Dravet syndrome and the mechanisms of action of fenfluramine, identified to date, have been summarized in the previous Eilat progress report. 22 The mechanisms responsible for the efficacy of fenfluramine in Dravet syndrome are under investigation. In a zebra fish model of Dravet syndrome, coadministration of antagonists of 5-HT receptor subtypes with fenfluramine in the mutant larvae suggests that 5-HT 1D , 5-HT 2C , and possibly 5-HT 2A receptor subtypes are involved with the antiseizure activity. 47 The σ1
receptor has also been implicated, suggesting nonserotonergic mechanisms may also play a role in the antiseizure effects of fenfluramine.
48,49
| Toxicology
Preclinical toxicology studies of fenfluramine have been summarized previously. 
| Pharmacokinetics
In a recent study in healthy volunteers, fenfluramine was absorbed with a t max of 3.0 hours after a single oral dose of ZX008 (0.8 mg/kg) and was eliminated with a terminal half-life of 20.1 hours. 51 In another study, administration of ZX008 to healthy volunteers after an overnight fast or 30 minutes after consumption of a high-fat breakfast resulted in similar exposures to the drug and to its major metabolite, norfenfluramine. 52 Preliminary receptor binding and functional assay experiments suggest that fenfluramine, norfenfluramine, and their enantiomers bind to and have effects at receptors identified in the literature as having a role in epilepsy. The metabolism of fenfluramine occurs via multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2D6, CYP2C9, CYP2C19, and CYP3A4. 22, 50 The pharmacokinetics of fenfluramine in patients with Dravet syndrome has not been reported to date.
| Drug interactions
Results of a study investigating potential drug-drug interactions of fenfluramine with other AEDs were recently presented. 51 Healthy volunteers were treated with a single dose of ZX008 (0.8 mg/kg), a single dose of stiripentol (3500 mg)/clobazam (20 mg)/valproate (25 mg/kg, maximum dose = 1500 mg) in combination, and a single dose of ZX008 plus the three-drug combination, with the treatments separated by 17 days. The three-drug combination increased the AUC of fenfluramine by about 70% and reduced the AUC of the metabolite by about 40%. In contrast, ZX008 did not have any significant impact on the pharmacokinetic profiles of the three other drugs. When administering these drugs together, a downward dose adjustment of ZX008 may be warranted. It is important to note, however, that this was a single dose study, and that the pharmacokinetic interactions during multiple dosing have not been established.
| Efficacy data
Two cohorts including 21 patients with Dravet syndrome have been treated for between 1 and 29 years with fenfluramine, with reports of strong antiseizure efficacy. 53, 54 In the most recent "prospective" cohort, which began treatment in 2011, patients experienced a median 83% reduction in frequency of major motor seizures (defined as tonic-clonic, tonic, clonic, atonic, and myoclonic seizures lasting >30 seconds) while treated with fenfluramine for a median of 3 years (range = 0.8-6.6) compared to a 3-month baseline observation period. Recently, the results of the first phase III double-blind, randomized, placebo-controlled trial in 119 patients with Dravet syndrome aged 2-18 years have been reported. 55 Subjects were randomized to placebo, ZX008 0.2 mg/kg/d, or ZX008 0.8 mg/kg/d (1:1:1) and were treated for a total of 14 weeks. Treatments were administered orally in two equally divided doses taken with food approximately 12 hours apart. The study met its primary objective by demonstrating that ZX008 at 0.8 mg/kg/d was superior to placebo in reducing seizure frequency as adjunctive therapy. Compared to placebo, subjects treated with ZX008 0.8 mg/kg/d demonstrated a 63.9% greater reduction in monthly frequency of major motor seizures (defined in this study as hemiclonic, tonic, clonic, tonic-atonic, generalized tonic-clonic, and focal seizures with clear observable motor signs; P < 0.001). Subjects treated with ZX008 0.2 mg/kg/ d experienced a 33.7% greater reduction in monthly major motor seizure frequency compared with placebo (P = 0.019). In addition, 70% of subjects treated with ZX008 0.8 mg/kg/d (P < 0.001) and 41% of subjects treated with ZX008 0.2 mg/kg/d (P = 0.001) demonstrated ≥50% reduction in monthly frequency of major motor seizures compared with 7.5% in the placebo group.
Preliminary uncontrolled data suggest that ZX008 may also have antiseizure effects in patients with Lennox-Gastaut syndrome. In an open-label dose-finding study in 13 patients with Lennox-Gastaut syndrome, the frequency of major motor seizures (defined in this study as generalized tonic-clonic, tonic, atonic, and focal seizures with a motor component) declined from a median of 60 per month in the baseline period to 22 per month 12 weeks after adding ZX008 at doses from 0.2 to 0.8 mg/kg/d to their treatment regimens. 56 Nine patients continued into an extension study and have been treated for 3-15 additional months. At their last study visit, monthly seizure frequency over a total of 8-20 months had declined by 58% compared to baseline. 56 
| Tolerability and adverse effect profile
The most common treatment-related AEs reported in the two open-label cohorts of patients with Dravet syndrome are mild-to-moderate somnolence, fatigue, and anorexia. A similar AE profile was observed in the Lennox-Gastaut study.
In the phase III Dravet syndrome study, non-cardiacrelated treatment-emergent AEs recorded in ≥10% in any treatment group were diarrhea (7.5%, 30.8%, 17.5%, for the placebo, 0.2, and 0.8 mg/kg/d groups, respectively), weight decrease (0, 12.8%, 5.0%), decreased appetite (5.0%, 20.5%, 37.5%), constipation (0, 2.6%, 10.0%), and lethargy (5.0%, 10.3%, 17.5%). Five subjects in the ZX008 0.8 mg/ kg/d group (12.5%) discontinued the study early due to an AE. None of the subjects in the ZX008 0.2 mg/kg/d group or in the placebo group discontinued treatment early due to AEs.
A major concern about the use of fenfluramine is its association with cardiac valvulopathy and pulmonary hypertension when used to treat obesity in adults. 57 These cases occurred primarily in patients taking fenfluramine in combination with phentermine. 57, 58 
| Planned studies
Enrollment has been completed in the pivotal phase III double-blind, randomized, placebo-controlled studies assessing low-dose ZX008 (0. 
| GANAXOLONE
| Introduction and rationale for development
Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one), a synthetic analog of the progesterone metabolite allopregnanolone, is a positive allosteric modulator of the γ-aminobutyric acid (GABA) A receptor. Ganaxolone retains the GABA A receptor modulatory effects of allopregnanolone but does not activate the nuclear (classical) progesterone receptors. Ganaxolone acts at both synaptic and extrasynaptic GABA A receptors by interacting with binding sites that are different from those involved in the action of benzodiazepines. 22 A formulation of ganaxolone suitable for oral dosing has been developed.
The current indications for ganaxolone include programs in postpartum depression and orphan epilepsy indications including refractory SE and CDKL5 deficiency disorder.
| Pharmacology and toxicology
The preclinical pharmacology and toxicology profile of ganaxolone has been summarized in the prior EILAT XIII progress report. 22 Seizure protection has been demonstrated in a broad range of animal models, and unlike other GABA A receptor modulators, ganaxolone does not show tolerance to anticonvulsant activity. In a rat model of refractory SE, ganaxolone shows a longer duration of effect than the positive control allopregnanolone, an observation that supports current phase II studies of ganaxolone in refractory SE. 22 Ganaxolone did not show end organ toxicity in 6-month rat and 12-month dog studies.
| Pharmacokinetics
Multiple-dose studies of oral ganaxolone were conducted in healthy volunteers. At steady state, mean C max and AUC 0-12 hour were close to dose proportional at doses up to 600 mg b.i.d., with higher doses producing less than proportional increments in serum drug levels. In general, ganaxolone was rapidly absorbed following oral administration and median t max values during multiple dosing were attained in 2 hours and were independent of dose level. Mean C max in epilepsy patients and healthy volunteers exceeded 250 ng/mL with oral doses of 800 mg b.i.d. or higher, thereby providing a level of exposure which is expected to be effective for chronic oral treatment of mood disorders and refractory epilepsies such as CDKL5 deficiency disorder (Marinus Pharmaceuticals, data on file). Ganaxolone is eliminated by CYP3A4-mediated metabolism. Its half-life is multiphasic, with a dominant phase of 3-6 hours.
| Drug interactions
The combined data available to date suggest that ganaxolone has low potential to affect the disposition of other drugs. 22 However, the disposition of ganaxolone is influenced by CYP3A4 inducers and inhibitors. The data also suggest that, within the dose range tested in clinical studies, changes in ganaxolone concentrations caused by the presence of enzyme-inducing AEDs is unlikely to have a clinically significant effect on clinical response (Marinus Pharmaceuticals, data on file).
| Efficacy
Ganaxolone has been studied in a variety of epileptic conditions including West syndrome, focal onset seizures, PCDH19 epilepsy, Lennox-Gastaut syndrome, and CDKL5 deficiency disorder. Some of these studies have been summarized in previous Eilat progress reports. 22, 59 In an uncontrolled 26-week open-label phase II study of girls with PCDH19 epilepsy, treatment with ganaxolone up to 1800 mg/d (or up to 63 mg/kg/d if <30 kg) was associated with a reduction in seizure frequency at 6 months in approximately half the cohort (54%-100% in 4/11, 26%-33% in 2/11). In another uncontrolled 26-week open-label study of ganaxolone up to 1800 mg/d (or up to 63 mg/kg/d if <30 kg), conducted in eight children with Lennox-Gastaut syndrome and severe, treatment-resistant generalized tonic-clonic and/or drop seizures, the median percentage reduction in seizures at 6 months was 32% and the median percentage increase in seizure-free days was 33%. In a similar study in seven patients with CDKL5 deficiency disorder, the median percentage reduction in seizures at 6 months was 43% with a median percentage increase in seizure-free days of 78%. Ten of the 28 subjects from the three cohorts of this 6-month study enrolled into the 52-week extension study due to good, long-term seizure control, including four of the seven children with CDKL5 deficiency disorder.
In the phase III study 1042-0603 in patients with focal seizures (ClinicalTrials.gov identifier: NCT02358538), there was no statistically significant effect of ganaxolone compared to placebo in the primary analysis. A post hoc analysis, however, showed a statistically significant reduction in seizure frequency for those subjects on ganaxolone who were taking three or more concomitant AEDs compared to those receiving placebo. In this subgroup, ganaxolone was associated with a 20% greater reduction in median seizure frequency than placebo (P = 0.02). 60 Although numerically superior, there was no statistically significant effect of ganaxolone compared to placebo for those subjects taking fewer than three AEDs.
| Tolerability and adverse effect profile
In all completed placebo-controlled studies, the most frequently reported AEs in ganaxolone-treated subjects were CNS-related and included somnolence, dizziness, fatigue, and headache (Table 1) . As shown in Table 1 , in multiple placebo-controlled studies across multiple indications including epilepsy, few AEs were reported with ganaxolone that occurred at a rate higher than those reported in placebo-treated subjects. These AEs were generally mild and have always been reversible.
| Planned studies
Marinus Pharmaceuticals is currently testing oral ganaxolone in a phase II long-term extension study in children with PCDH19 epilepsy, CDKL5 deficiency disorder, and Lennox-Gastaut syndrome. A phase II study in refractory SE was initiated in early 2018 with intravenous ganaxolone. A phase III pivotal study of oral ganaxolone in patients with CDKL5 deficiency disorder will be initiated in 2018. 
| MEDIUM-CHAIN FATTY ACIDS
| Introduction and rationale for development
Medium-chain fatty acids, including decanoic acid, provide the key constituents of the medium-chain triglycerides (MCTs) in the MCT ketogenic diet. This diet provides one of the last options for the treatment of patients with refractory epilepsy and has been validated in a clinical trial in childhood epilepsy. 61 Although often effective, the diet is more commonly used in the treatment of pediatric patients rather than adults, due to the stringent dietary restrictions. The mechanism of the ketogenic diet is broadly considered to be through the hydrolysis of triglycerides to release free fatty acids (decanoic acid and octanoic acid, in the case of the MCT diet) that are metabolized to ketones to provide seizure control. 61 This mechanism has recently been challenged, with the proposal that decanoic acid functions as the therapeutic component of the diet, 62 and that this mechanism can be reproduced by specific related congeners. Decanoic acid was first suggested as the active component of the diet from research in a simple biomedical model 63 where a range of novel fatty acids were proposed as seizure control treatments. Several of these fats have been subsequently validated in a range of in vitro and in vivo models. 64, 65 Further analysis of decanoic acid showed that it functions to block activity in two acute ex vivo rat hippocampal slice models of epileptiform activity, and this effect was not evident for ketones or octanoic acid. 65 
| Pharmacology
Release of decanoic acid from triglycerides in the gastrointestinal tract enables direct absorption through the gut wall, where it is mostly metabolized in the liver through β-oxidation to produce ketone bodies. However, some fatty acids escape into the circulatory system. In animal models, decanoic acid has been found to penetrate the blood-brain barrier and to be present in brain at 60%-80% of serum levels. 66 In the brain, decanoic acid functions as a noncompetitive inhibitor of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, 62 with a half-maximal inhibitory concentration (IC 50 ) of 0.52 ± 0.02 mmol/L. This is considerably lower than that for octanoic acid (IC 50 = 3.82 ± 0.03 mmol/L).
| Anticonvulsant profile in animal models
Decanoic acid (1 mmol/L) blocks PTZ-or low magnesiuminduced epileptiform discharges in rat entorhinal cortexhippocampus slices within 20 minutes of exposure.
62,64
The first study to show an antiseizure effect of decanoic acid involved ip administration to mice 15 minutes before seizure induction by subcutaneous injections of picrotoxin. Decanoic acid caused a small but significant delay in the onset to clonic convulsions at 172 mg/kg (from around 480 seconds without treatment to around 970 seconds with T A B L E 1 Integrated table of adverse events from placebocontrolled studies of ganaxolone (≥5% for ganaxolone as of January, 2018)
Adverse Events Ganaxolone, n = 750 Placebo, n = 540
Somnolence, n (%) 134 (18) 31 (6) Dizziness, n (%) 95 (13) 24 (4) Fatigue, n (%) 51 (7) 21 (4) Headache, n (%) 37 (5) 28 (5) As noted in Table 3 , across multiple placebo-controlled studies of ganaxolone, across multiple indications including epilepsy, few side effects are reported that occur at a rate higher than those reported in placebo-treated subjects. These side effects are generally mild and have always been reversible.
decanoic acid), whereas fatty acids with longer chain lengths caused greatly increasing onset time, with palmitic acid (16 carbons) delaying convulsions to around 3600 seconds; decanoic acid did not increase survival time. 67 Using the same administration route, this study also suggested that onset to clonic seizures induced by subcutaneous PTZ was not affected by decanoic acid at 172 mg/kg, but survival times increased from around 422-633 seconds. Although this study suggested a weak effect of decanoic acid on seizure activity, the small effect size and inconsistency between models did not provide strong evidence for an antiseizure effect. However, two subsequent studies did suggest a role for decanoic acid in seizure control. Using a single bolus oral gavage dose of decanoic acid, seizure thresholds in the 6 Hz model were significantly increased (at 1.7 and 5.2 g/ kg), and a similar increase in the maximal electroshock threshold was observed at 8.6 g/kg per os, 66 although no effect was observed at decanoic acid doses up to 8.6 g/kg per os following seizure induction with intravenous PTZ. In addition, dietary intake of 35% of calories through decanoic acid (only) triglycerides increased seizure threshold in the 6 Hz model and the latency to first generalized seizure in the flurothyl model. 68 These effects were not seen following octanoic acid (only) triglyceride dietary intake. Importantly, this study also demonstrated that both decanoic acid and octanoic acid triglycerides provided a common level of ketosis, but only the decanoic acid diet provided seizure control, strongly supporting a role for decanoic acid in seizure control independent of ketone generation. In addition to decanoic acid, a range of congeners, including branched and cyclic derivatives, also show strong seizure control activity.
62,64,65
| Other pharmacological properties
Decanoic acid has been shown to increase mitochondrial proliferation through the regulation of a fatty acid receptor, PPARγ. 69 In this study, decanoic acid treatment of cultured neural cells was shown to act via PPARγ to enhance mitochondrial biogenesis and activity of the mitochondrial complex I. This mechanism was not evident for octanoic acid and is thought to increase adenosine triphosphate availability, leading to an increase in seizure threshold and to a reduction in seizure activity following longterm treatment.
| Mechanisms of action
Studies using whole-cell patch-clamp recordings from CA1 pyramidal neurons have shown that decanoic acid reduces excitatory postsynaptic currents, consistent with an effect on postsynaptic excitatory AMPA receptors. 62 Direct inhibitory activity of decanoic acid against AMPA receptors was then shown using a Xenopus oocyte model, where the expression of distinct AMPA receptor subunits (GluA1, GluA2, and GluA3) enabled the detailed analysis of decanoic acid-dependent inhibition in isolated receptors. 62 In silico docking analysis suggests decanoic acid binds to AMPA receptors on the M3 helices within the channel region, 62 providing a distinct binding site to that proposed for perampanel-a currently licensed treatment for focal and generalized tonic-clonic seizures through AMPA receptor inhibition. Decanoic acid directly inhibits AMPA receptors of different subunit combinations, with greatest potency against GluA2/3 (IC 50 = 0.52 mmol/L), followed by GluA1/2 (IC 50 = 1.16 mmol/L) and then GluA1 only (IC 50 = 2.09 mmol/L). This suggests activity against the most common receptor combinations in the mammalian brain. 62 Furthermore, the inhibitory effect of decanoic acid against AMPA receptors is voltage-dependent, where potency against GluA2/3 receptors at −80 mV (IC 50 = 1.11 mmol/L) is enhanced under a more depolarized condition at −40 mV (to IC 50 = 0.43 mmol/L), suggesting stronger inhibitory activity during prolonged seizure activity.
| Toxicology
Few reports of decanoic acid toxicology have been published. Unpublished data kindly provided by the Epilepsy Therapy Screening Program suggest no behavioral toxicity in mice at up to 300 mg/kg (ip). High-concentration single bolus gavage experiments in mice suggest impaired motor performance in the chimney test, with a median toxic dose of 17.6 g/kg, and no single dose was shown to significantly impair grip strength. 66 
| Pharmacokinetics
Several early studies have monitored medium-chain fats in peripheral blood from children on the MCT ketogenic diet (reviewed by Augustin et al 61 ). These studies show wide variation in decanoic acid levels (87-552 μmol/L, with an average of 157 μmol/L). In contrast, patients had greater levels of octanoic acid, averaging 310 μmol/L, a finding that may reflect the higher content of octanoic acid provided within the MCT supplement. Although octanoic acid is unlikely to inhibit AMPA receptors at therapeutic concentrations, it may function to elevate neuronal decanoic acid levels through preferential oxidation. 61 
| Drug interactions
Contraindications for the ketogenic diet include defects in fatty acid metabolism and function including fatty acid oxidation, and deficiencies in carnitine-related function, organic translocase, pyruvate carboxylase, and hypoglycemia.
| Efficacy data
A randomized trial suggested that the classical and the MCT ketogenic diets may show similar efficacy in seizure control, although the classical diet requires a more stringent regimen. 70 In that trial, the classical diet and the MCT diet were administered to a total of 125 children with pharmacoresistant epilepsy, but only 47 patients were evaluable for efficacy at the 12-month assessment. The average percentage decrease in seizure frequency compared with baseline was 53% for the evaluable children in the MCT ketogenic diet group (n = 25) and 40.8% for those evaluable in the classical ketogenic diet group (n = 22). No breakdown of outcome by seizure type was reported.
| Tolerability and adverse effect profile
Although no data exist regarding decanoic acid-only treatment in patient groups, the MCT ketogenic diet is associated with a range of gastrointestinal-related side effects, such as cramps, bloating, diarrhea, and vomiting. In addition, it is important to note that AMPA receptors play an important role in synaptic strengthening during long-term potentiation and synaptic plasticity. However, inhibition of AMPA receptor activity has been demonstrated not to impair long-term potentiation or cognition (for review, see Chang et al 62 ) , suggesting that dietary decanoic acid is unlikely to adversely affect learning and memory. In contrast, the MCT ketogenic diet has been suggested to be possibly associated with positive effects on cognition. 71 
| Planned studies
A recently developed modified MCT diet containing high levels of decanoic acid (Betashot) is currently in tolerability clinical trials with both adult and pediatric drug-resistant patients (NCT02825745). This study involves less stringent dietary restrictions than the currently used MCT ketogenic diet. 
| PADSEVONIL
| Introduction and rationale for development
Benzodiazepines, which enhance inhibitory GABAergic neurotransmission, were observed to markedly potentiate the anticonvulsant activity of the synaptic vesicle 2A (SV2A) ligand levetiracetam in a variety of seizure models, with no exacerbation of side effects. 72 These observations led to a rational medicinal chemistry design program to develop a molecule combining presynaptic activity (high-affinity binding to SV2) with postsynaptic enhancement of GABAergic inhibition (low-to-moderate affinity binding at the benzodiazepine site of the GABA A receptor). Padsevonil (UCB0942) is the first rationally designed AED candidate that inhibits seizure activity by presynaptic modulation of all three SV2 isoforms and postsynaptic enhancement of GABA-mediated inhibition.
| Pharmacology
| Anticonvulsant profile in animal models
The antiseizure profile of padsevonil differs considerably from that of selective SV2A ligands. Padsevonil showed substantially higher potency than levetiracetam and brivaracetam across a range of acute seizure models, including several where levetiracetam and brivaracetam show no or limited efficacy (Table 2) . 73 Interestingly, padsevonil offered significantly greater protection against seizures than a simple combination of AEDs that target SV2A and GABA A receptors (levetiracetam or brivaracetam in combination with diazepam) at doses resulting in similar target occupancies. 73 This might be because of padsevonil's unique SV2A binding mode (see below), the additional interaction with SV2B and SV2C, and the partial agonism at the benzodiazepine receptor.
73
Amygdala kindling is the most characterized chronic model for focal seizures and is used to further evaluate the activity of AED candidates. 74 Activity in the amygdala kindling model has been shown to be predictive of efficacy against focal to bilateral tonic-clonic seizures in the clinical setting. 74 Padsevonil displayed potent activity in fully kindled mice and rats. It provided complete protection against focal to bilateral tonic-clonic seizures and significantly reduced both seizure severity and afterdischarge duration, indicating activity against local seizure discharge and spread (Table 2) . 75 Adverse effects on the motor performance of mice were evaluated in the rotarod test. Padsevonil displayed a high therapeutic index in the pilocarpine, audiogenic, and 6 Hz models, as well as in the mouse amygdala kindling model, indicating a large margin between doses that provide a therapeutic effect and those that induce side effects.
73,75
| Receptor occupancy
At the dose range providing seizure protection in amygdala kindling models, padsevonil occupancy of SV2A proteins is high, whereas occupancy of the benzodiazepine site is low. Two positron emission tomography (PET) studies were conducted in humans to evaluate occupancy at the same receptor targets after therapeutically relevant doses. 76 Modeling of these PET data confirmed a pattern similar to the preclinical model. For SV2A, there is sustained highlevel (>90%) receptor occupancy at padsevonil doses of ≥100 mg b.i.d., whereas for GABA A , there is transient low but quantifiable receptor occupancy at padsevonil doses of ≥200 mg b.i. d. (200 mg b. i.d.: 6.4%; 400 mg b.i.d.: 13.4%). 76 These PET studies allowed projection of a quantitatively based dosing rationale for future clinical trials of padsevonil and indicated that the 400 mg b.i.d. dose selected for the proof-of-concept trial achieves desired target occupancies.
| Mechanism of action
Padsevonil has a unique mechanism of action. Unlike levetiracetam and brivaracetam, which selectively bind to SV2A, 77 padsevonil binds with high affinity to all three isoforms of the SV2 protein: SV2A (pKi 8.5), SV2B (pKi 7.9), and SV2C (pKi 8.5). 78 Some data indicate that SV2B and SV2C might play a role in the pathogenesis of epilepsy and other neurodegenerative diseases. 77 The way padsevonil interacts with SV2A also differs from levetiracetam and brivaracetam. With a dissociation half-life of 29 minutes, padsevonil has slower kinetics at SV2A than levetiracetam and brivaracetam (too fast to measure at 37°C), indicating that it engages with SV2A proteins for longer. 78 Furthermore, padsevonil has approximately 100-1000 times higher binding affinity for SV2A than brivaracetam or levetiracetam (pKi 8.5 vs 6.6 and 5.2, respectively). 78 Postsynaptically, padsevonil binds with moderate affinity to the benzodiazepine binding site of the GABA A receptor, where it acts as a partial agonist. 78, 79 Drug tolerance is an important clinical concern, which limits chronic use of benzodiazepines for epilepsy treatment. 80, 81 Agents with lower intrinsic efficacy at the benzodiazepine receptor could be associated with a lower likelihood of tolerance, and padsevonil may display a reduced potential for tolerance induction, as previously demonstrated for other partial GABA A agonists in animal models. 79, 81 Padsevonil maintained anticonvulsant activity after repeated administration in mice, whereas treatment with diazepam under the same experimental conditions was associated with a significant loss of activity (UCB Pharma, data on file). These data suggest minimal potential for tolerance development with padsevonil, consistent with its moderate affinity and partial agonism at the benzodiazepine site.
| Pharmacokinetics and metabolic profile
In two phase I ascending dose trials (single dose up to 490 mg, multiple dose up to 400 mg b.i.d.) in healthy volunteers (n = 6 and n = 10 per dose, respectively), the pharmacokinetic profile of padsevonil demonstrated high intersubject variability (>50% in AUC). 82 After single oral doses ranging between 10 and 490 mg, exposure to padsevonil (C max and AUC) increased linearly with dose. Concentration-time profiles demonstrated a short time to peak and a biphasic disposition with a median terminal half-life of~6-7 hours. After a single dose, padsevonil CL/F was~70 L/h and independent of dose within the 30-490 mg dose range. After multiple dosing (100-400 mg b.i.d.), the clearance of padsevonil decreased, resulting in an increase in exposure (1.5-to twofold higher than after a single dose) and steady state was reached after 2-3 days of dosing. Renal excretion of padsevonil was low (<0.06%). Pharmacokinetic data supported a twice daily dosing regimen, and tolerability data indicated 400 mg b.i.d. as the maximum tolerated dose. 82 
| Drug interactions
Because the metabolism of padsevonil is mediated by CYP isoforms, the potential for drug interactions with enzymeinducing/inhibiting drugs is being thoroughly evaluated.
| Efficacy data
A randomized, double-blind, placebo-controlled phase II trial (EP0069, NCT02495844) enrolled adult patients (≥18 years) with ≥4 observable focal seizures per week (includes focal aware with motor symptoms, focal impaired awareness, and focal to bilateral tonic-clonic seizures), who had failed to achieve seizure control with ≥4 AED regimens of adequate dose and duration and were on a stable dose of ≥1 AED. 83 Concomitant treatment with drugs known to induce CYP3A4 enzymes was prohibited. After a 2-week prospective baseline, patients were randomized (1:1) to receive padsevonil or placebo concomitantly with their current, stable AED regimen and entered a 3-week double-blind inpatient period. In the padsevonil arm, treatment was initiated at 100 mg/d and doses were uptitrated to 400 mg bid (maximum tolerated dose) over 1 week, followed by a 2-week inpatient maintenance. In the placebo arm, 2-week maintenance was followed by uptitration to 400 mg b.i.d. padsevonil in week 3. All patients continued on padsevonil in an 8-week open-label outpatient period. The primary efficacy outcome was the 75% responder rate (≥75% reduction in observable focal seizure frequency) from 2-week baseline to 2-week inpatient period (last 2 weeks for padsevonil vs first 2 weeks on placebo). The first secondary efficacy outcome was the median reduction in seizure frequency. 83 A total of 55 patients were randomized (padsevonil: 28; placebo: 27). Patients had a median duration of epilepsy of 24.2 years and a median baseline seizure frequency of 8.24 seizures per week, which is more than three times the frequency generally observed in AED clinical trial programs. Overall, 75% of patients had ≥8 prior AEDs (including those at baseline). The majority of patients were taking two or more concomitant AEDs (1 AED: 9.1%; 2 AEDs: 30.9%; 3 AEDs: 32.7%; ≥4 AEDs: 27.3%), most commonly levetiracetam (36.4%), lacosamide (30.9%), and oxcarbazepine (30.9%). During the 2-week inpatient maintenance, eight of 26 patients (30.8%) on padsevonil versus three of 27 patients (11.1%) on placebo had a ≥75% reduction in focal seizure frequency from the baseline period (odds ratio = 4.14, P = 0.0679). The median percentage reduction in weekly focal seizure frequency from baseline to the 2-week inpatient period was 53.7% with padsevonil versus 12.5% with placebo. The median difference was 34.0% (95% CI = 3.0, 67.5; P = 0.026 [not adjusted for multiplicity]). Two patients on padsevonil and one on placebo were seizure-free during the inpatient period. Overall, 53 of 55 patients continued to the outpatient open-label padsevonil treatment. During the last 4 weeks of outpatient padsevonil treatment, 16 of 51 patients (31.4%) were ≥75% responders, demonstrating maintenance of seizure control during the outpatient period. The median percentage reduction in weekly focal seizure was 55.2% (n = 51). No patients were seizure-free for the entire trial period. Fifty patients completed the trial. 
| Tolerability and adverse effect profile
In two phase I trials in healthy volunteers, padsevonil was generally well tolerated at doses up to 400 mg b.i.d. 82 Transient, self-limiting CNS AEs (fatigue, somnolence, dizziness, disturbance in attention) occurred with increasing frequency at higher doses but attenuated with repeated doses. One serious AE of delirium occurred 2 days after the final padsevonil dose and was attributed to padsevonil. One healthy volunteer withdrew due to fatigue. At the highest doses (≥400 mg/d), transient reductions were seen in memory, alertness, psychomotor performance, and vigilance that lessened with repeated dosing. 82 In the proof-of-concept trial, the most common treatment-emergent AEs (TEAEs) with padsevonil were CNSrelated, consistent with its pharmacology. 83 22, 59, 85 Since the previous EILAT progress report, 22 new results have been acquired with both valnoctamide and sec-butylpropylacetamide.
| Pharmacology
| Anticonvulsant profile in animal models
The activity of racemic valnoctamide and racemic secbutylpropylacetamide has been assessed in a model of SE in which seizures were induced by tetramethylenedisulfotetramine (TETS), a highly lethal neurotoxic rodenticide that acts as a noncompetitive GABA A receptor antagonist. For comparison, valproic acid was also evaluated in the same model. Severe TETS intoxication in humans is often associated with refractory convulsive SE. 86 Mice were pretreated with a single dose of riluzole (10 mg/kg ip) and 10 minutes later received a lethal dose of TETS (0.2 mg/kg ip). Riluzole does not inhibit TETS-induced SE but does protect against the rapidly lethal effects of TETS in mice, providing a model of persistent seizure activity. Behavioral seizure activity was assessed by visual observation, and the latency to cessation of SE was recorded. Animals were monitored for 7 days after seizure termination. Latency to cessation of SE was defined as the interval between the first behavioral myoclonic twitch and termination of seizure activity. sec-Butylpropylacetamide, valnoctamide, and valproic acid were administered ip at 40 minutes after the first myoclonic twitch. sec-Butylpropylacetamide at doses of 54 and 100 mg/kg terminated SE within~4 and~2 minutes, respectively, and protected 65% and 100% of animals from mortality for >7 days. Valnoctamide at doses of 50 and 100 mg/kg terminated SE within~7 and~2 minutes, respectively, and protected 62.5% and 90% of animals from mortality. Both sec-butylpropylacetamide and valnoctamide produced sedation in treated animals, which was especially pronounced at the dose of 100 mg/kg. Valproic acid (100 mg/kg) terminated TETS SE transiently in 80% of animals, and only 20% animals survived. A high valproic acid dose (200 mg/kg) terminated SE within~8.8 minutes and protected 80% of animals from mortality. Vehicle treatment failed to terminate TETS SE, resulting in delayed mortality (within 2 hours) in 57%-80% of the animals depending on the percentage of the vehicle components (water, alcohol, and propylene glycol) and its injected volume. In conclusion, both sec-butylpropylacetamide and valnoctamide effectively terminate TETS-induced behavioral SE, protect animals from mortality, and are more potent and more rapidly acting than valproic acid. 86 In separate studies, sec-butylpropylacetamide and valnoctamide were tested, in comparison with phenobarbital, for their ability to antagonize organophosphate nerve agent-induced seizures in juvenile rats and to evaluate their potential to treat benzodiazepine-resistant SE. The rationale for conducting these studies is that children are likely to be among the casualties in a civilian nerve agent exposure, and because this population is particularly susceptible to seizures when compared to adults, [87] [88] [89] the activity of anticonvulsants used to treat nerve agent-induced seizures needs to be studied early in life. Although models of nerve agent-induced seizures to test antiseizure activity in adult animals have been around for years, 90 one of the first models to conduct these tests during the first weeks postnatally was developed only recently (Ardinger et al, personal communication). 91 Female and male postnatal day (PND) 21
and 28 and PND 70 adult control rats were implanted with electroencephalographic headpieces and exposed to seizureinducing doses of the organophosphate nerve agents sarin or VX. Five minutes after seizure onset, animals were treated by the ip route with sec-butylpropylacetamide, valnoctamide, or phenobarbital, three drugs that enhance GABAergic signaling. 22 The up-down method was used to determine the anticonvulsant ED 50 of each of the three drugs. In the up-down method, 92 an initial testing dose is chosen, usually based on previous work, and then a succession of doses in 0.20-0.25 log units above and below this starting dose are chosen at fixed steps between doses. The first animal is tested at the initial dose, and if this dose terminates the seizure, the next test animal is tested at the next lower dose, whereas if the initial test dose does not terminate the seizure the next test animal is tested at the next higher dose. The rule is if the seizure is terminated, go down a dose in the next test animal; if the seizure is not terminated, go up a dose in the next test animal. Testing proceeded in this fashion until four reversals occurred. The results of these experiments are shown Table 3 . In general, there were little differences between sexes within a given age group. The most notable differences were at PND 28, with males requiring higher doses of sec-butylpropylacetamide than females in both the VX and the sarin models. For sec-butylpropylacetamide, ED 50 values were relatively homogeneous across age groups in the sarin model, whereas higher doses were required at PND 28 and PND 70 males relative to PND 21 males in the VX model.
| Toxicology
| Mitochondrial liver toxicity
Liver toxicity is an established adverse effect of valproic acid, which is particularly problematic for patients with mitochondrial disorders. The comparative mitochondrial toxicity of valproic acid, valnoctamide, sec-butylpropylacetamide, and their corresponding acids (and valproic acid analogues) was determined by studying their effect on respiration rate of isolated rat brain and rat liver mitochondria. Specific effects on mitochondrial pyruvate transport were evaluated by swelling experiments. 93 Whereas the pyruvate and 2-oxoglutarate oxidation rates of rat brain mitochondria were nearly unaffected by valproic acid, rat liver mitochondrial pyruvate and 2-oxoglutarate oxidation were severely impaired by valproic acid concentrations > 100 μmol/L. Among the reactions involved in pyruvate oxidation, pyruvate transport and dehydrogenation steps were not affected by valproic acid, whereas α-lipoamide dehydrogenase was strongly inhibited (IC 50 = 80 μmol/L). A similar inhibition of α-lipoamide dehydrogenase (IC 50 = 100 μmol/L) was also caused by valproic acid's one-carbon homolog secbutylpropylacetic acid (sec-butylpropylacetamide's corresponding acid) and to a lesser extent (IC 50 = 300 μmol/L) by valproic acid's constitutional isomer valnoctic acid (valnoctamide's corresponding acid), whereas the corresponding amides of the above three acids (valpromide, sec-butylpropylacetamide, and valnoctamide) showed only small effects (IC 50 > 1 mmol/L).
In conclusion, the active intrinsic inhibitors of pyruvate and 2-oxoglutarate oxidation are most likely to be the coenzyme A conjugates of valproic acid and its acid analogues sec-butylpropylacetic acid and valnoctic acid, which selectively affect α-lipoamide dehydrogenase in liver. The valproic acid amide derivatives valnoctamide and sec-butylpropylacetamide showed low inhibitory effects on mitochondrial oxidative phosphorylation in liver, which might T A B L E 3 Activity of sec-butylpropylacetamide, valnoctamide, or phenobarbital, given intraperitoneally, in protecting against seizures induced nerve agents VX and sarin in M and F rats assessed at PND 21, 28, and 70 50 result in these compounds having reduced hepatotoxicity risk in patients with epilepsy associated with mitochondrial disorders. 93 
Inhibition of VX-induced seizures, ED
| Efficacy and adverse effect profile of valnoctamide in patients with acute mania
Women of child-bearing age with bipolar disorder face a dilemma when pregnant, as most mood stabilizers have teratogenic potential. 94, 95 Intense research has been aimed at designing nonteratogenic CNS-active valproic acid derivatives retaining antiepileptic and mood-stabilizing properties. 96, 97 In a head-to-head comparison, valnoctamide unlike valproic acid was found to be nonteratogenic in mice, rats, and rabbits. 22, 59 These promising results led to the conduction of a double-blind randomized trial to assess the efficacy and safety of valnoctamide monotherapy in comparison to placebo and to risperidone, used as an active control, in the treatment of patients with an acute manic episode.
Unlike the preclinical candidate sec-butylpropylacetamide, valnoctamide was commercially available in Europe as an anxiolytic agent and underwent an earlier clinical trial in bipolar disorder, because this was the preferred indication of the funding institution (the Stanley Medical Research Institute). 98, 99 This 3-week parallel group trial, for which preliminary results were reported in a previous EILAT progress report, 59 was conducted in 173 patients in an acute manic episode, who were randomized to receive valnoctamide 1500 mg/d given three times daily (n = 71), risperidone 6 mg/d given three times daily (n = 32), or matching placebo (n = 70). The primary outcome measure was the change in Young Mania Rating Scale (YMRS) score. The Clinical Global Impression Scale for Bipolar Disorder was also utilized, as well as the Positive and Negative Syndrome Scale to evaluate psychosis. Samples for the determination of plasma valnoctamide concentrations were collected at the end-of-study visit. 98 Valnoctamide did not differ significantly from placebo on any of the study endpoints. However, in the per-protocol analysis, changes in total YMRS scores showed a trend of significance (P = 0.17) in favor of valnoctamide. Risperidone also failed to show superiority to placebo for YMRS score changes compared to baseline (P = 0.32). Mixed models for repeated measures showed that risperidone produced significantly more improvement than placebo in the overall Clinical Global Impression Scale for Bipolar Disorder (P = 0.036) and the severity scale for mania (P = 0.021). No significant correlation was observed between plasma valnoctamide levels and change in symptom severity (r = 0.045, P = 0.790); however, interpretation of this finding should take into account that valnoctamide levels were measured at various times after dosing. The Kaplan-Meier survival curve revealed higher discontinuation rates, mainly due to lack of efficacy, in the valnoctamide group compared to the other study groups (P = 0.026).
The overall frequency of AEs was 32.9% in the placebo group, 36.6% in the valnoctamide group, and 56.3% in the risperidone group. A Cox regression model analysis showed that the risperidone group discontinued treatment due to AEs sooner than the placebo group (P = 0.01). The same was found for the valnoctamide group compared with the placebo group, but the difference just failed to reach statistical significance (P = 0.052).
The study indicated that valnoctamide 1500 mg/d as monotherapy was well tolerated but lacked efficacy in patients with acute mania. These results differ from those reported by Bersudsky et al, 99 who found that dual therapy with valnoctamide and risperidone was superior to risperidone monotherapy in more severely ill patients (mean YMRS of 34, compared with 29 in the latest study). These results suggest that valnoctamide, at least in combination with risperidone, might be efficacious in more severely affected population, particularly because it is known that in general more severely ill patients show greater therapeutic response to antimanic drugs. 99 The limitations of the latest study are further highlighted in that in the same study risperidone itself failed to do better than placebo in improving the primary outcome measure, although it should be acknowledged that the sample size for the risperidone group was smaller. 98 Overall, further studies on the therapeutic potential of valnoctamide as an antimanic medication appear to be justified, particularly in the light of its good tolerability and its lack of teratogenic activity in animal models, which is an incentive to assess valnoctamide for its potential efficacy in epilepsy as a second generation to valproic acid.
96,97
| CONCLUSIONS
Review of the data presented at the EILAT XIV Conference, summarized in this report and in an accompanying article, 1 indicates that major efforts in preclinical and clinical research are continuing in order to develop novel AEDs. The overarching aim is to discover treatments with superior efficacy and safety compared with existing agents, especially for the management of patients with difficult to treat epilepsies. These efforts build to a large extent on advances that have been made in understanding the mechanisms of epileptogenesis and ictogenesis, as well as the mechanisms of action of existing treatments. The methodological approaches used in the discovery and development of these compounds show an increasing utilization of sophisticated preclinical models, including those designed to mimic pharmacoresistance, those that permit evaluation of potential antiepileptogenic effects, and those that replicate specific genetic defects found to be causative of epilepsy. In terms of clinical targets, an interesting observation is the trend of focusing on orphan epilepsy syndromes, particularly severe epileptic encephalopathies with onset in early age. In the case of compounds for which at least preliminary clinical efficacy data were presented, the rationale for development shows remarkable diversity. Some molecules (eg, decanoic acid) are being developed based on initial evidence derived from dietary treatments, whereas for others, such as cannabidiol for Dravet syndrome and Lennox-Gastaut syndrome, or fenfluramine for Dravet syndrome, the incentive to conduct placebo-controlled randomized controlled trials originated largely from evidence generated by early uncontrolled observations. The rationale for developing valproic acid derivatives and padsevonil was to improve activity profiles through structure modification, which in the case of padsevonil also aimed at exploiting potential synergism between the properties of different drug classes. The rationale for developing ganaxolone relates to research on neurosteroids as modulators of neuronal excitability, whereas in the case of anakinra initial exploratory use in selected patients was triggered by research on the role of neuroinflammation in the pathogenesis of some epilepsies. Further studies with each of these agents are continuing, and it is likely that at least some of them will be approved for routine clinical use in the near future.
